KUR-101 is under clinical development by Atai Life Sciences and currently in Phase I for Pain. According to GlobalData, Phase I drugs for Pain have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how KUR-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

KUR-101 overview

KUR-101 (deuterated mitragynine) is under investigation for the treatment of pain and opioid use disorder. The drug candidate is a synthetic derivative of alkaloid derived from Mitragyna speciosa plant (kratom) and acts by targeting human mu opioid receptors and human Kappa opioid receptors. It is administered through oral route. 

Atai Life Sciences overview

Atai Life Sciences (ALS) is a biotechnology company that develops innovative treatments for addressing unmet medical needs and mental health disorders. ALS is headquartered in Munchen, Germany.

For a complete picture of KUR-101’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.